Fosravuconazole
- Product Name
- Fosravuconazole
- CAS No.
- 351227-64-0
- Chemical Name
- Fosravuconazole
- Synonyms
- E-1224);BMS-379224;Fosravuconazole;CAS:351227-64-0;SYTNEMZCCLUTNX-NPMXOYFQSA-N;Fosravuconazole (Synonyms: BMS-379224;Benzonitrile, 4-[2-[(1R,2R)-2-(2,4-difluorophenyl)-1-methyl-2-[(phosphonooxy)methoxy]-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]-
- CBNumber
- CB23159905
- Molecular Formula
- C23H20F2N5O5PS
- Formula Weight
- 547.47
- MOL File
- 351227-64-0.mol
Fosravuconazole Property
- Boiling point:
- 783.7±70.0 °C(Predicted)
- Density
- 1.52±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- form
- Solid
- pka
- 1?+-.0.10(Predicted)
- color
- Off-white to light yellow
Fosravuconazole Chemical Properties,Usage,Production
Uses
Fosravuconazole (BMS-379224), a proagent of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravuconazole can be used for candidiasis, onychomycosis and parasitemia research[1][2][3].
Definition
ChEBI: BMS 379224 is an amine.
in vivo
Fosravuconazole (E-1224; 10-50 mg/kg; oral administration; daily; for 20 days) treatment suppresses the parasitemia and prevents death in mice infected with the T. cruzi Y strain[3].
| Animal Model: | Swiss female mice (20-24 g) inoculated with trypomastigotes (Y strain)[3]. |
| Dosage: | 10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg, 50 mg/kg |
| Administration: | Oral administration; daily; for 20 days |
| Result: | Suppressed the parasitemia and prevented death. |
References
[1] Shinichi Watanabe, et al. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study. J Dermatol. 2018 Oct;45(10):1151-1159. DOI:10.1111/1346-8138.14607
[2] Katsura Hata, et al. Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases. Parasitol Int. 2020 Dec 25;81:102278. DOI:10.1016/j.parint.2020.102278
[3] Lívia de Figueiredo Diniz, et al. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice. Antimicrob Agents Chemother. 2018 May 25;62(6):e00401-18. DOI:10.1128/AAC.00401-18
Fosravuconazole Preparation Products And Raw materials
Raw materials
Preparation Products
Fosravuconazole Suppliers
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 19962
- Advantage
- 58